DARMSTADT, Germany – Merck KGaA is collaborating with Medisafe on a customized version of Medisafe’s mobile medication adherence platform for cardiometabolic patients. Plans for the platform include reminders, motivation and support systems, targeted content, coupons and interventions in the user’s local language. “This is an extremely important step toward realizing our vision of supporting patients with comprehensive, integrated, value-added services that look beyond medicines to improve treatment outcomes,” said Simon Sturge, COO at Merck KGaA, in a statement. “We are confident that offering such a solution to our patients has the potential to significantly improve medication adherence by giving patients and caregivers the tools to organize, understand and manage their medications.” The new digital solution will complement Merck KGaA´s current offering of primary care medicines for cardiometabolic conditions, which includes treatments for Type 2 diabetes, thyroid disorders and cardiovascular diseases.
